Cryptotanshinone (CPT), isolated from the plant Salvia miltiorrhiza Bunge, is a potential anticancer agent. However, the underlying mechanism remains to be defined.
Introduction

Cryptotanshinone (CPT), a natural compound isolated from Salvia miltiorrhiza
Bunge (Danshen), has been used in traditional oriental medicine for the treatment of a variety of diseases, such as coronary artery disease (1), hyperlipidemia, acute ischemic stroke (2) , chronic renal failure (3), chronic hepatitis (4) , and Alzheimer's disease (5) . In addition, CPT has been recently shown to possess anticancer activity in a spectrum of human cancer cells (6) (7) (8) (9) (10) . For instance, CPT inhibits growth of prostate cancer cells (DU145) by inactivating the signal transducer and activator of transcription-3 (Stat3) activity (6) ; induces apoptosis in DU145 cells by augmenting Fas sensitivity (7) ; inhibits growth of hepatocarcinoma and gastric cancer cells by arresting cell cycle at S phase (8) ; and inhibits proliferation of skin cancer cells (B16 and B16BL6) (9) . Most recently we have further demonstrated that CPT displayed anticancer activity by inhibiting proliferation of human rhabdomyosarcoma (Rh30), prostate cancer (DU145) and breast cancer cells (MCF-7), by arresting cells in G 1 /G 0 phase of the cell cycle (10) . CPT inhibition of cell proliferation was associated with downregulation of cyclin D1 expression and phosphorylation of retinoblastoma (Rb) protein, due to inhibition of the mammalian target of rapamycin (mTOR) signaling pathway (10) . These findings suggest that CPT is a potential novel anticancer agent.
Lymphangiogenesis, like angiogenesis, plays an important role in promoting tumor growth and metastasis (11) (12) (13) . For many types of solid tumors, the lymphatic system acts as the primary conduit for initial metastasis, which is an indication of disease progression and prognosis for reduced survival (14) (15) (16) (17) . Therefore, inhibition of lymphangiogenesis is a promising strategy for treatment or prevention of tumor metastasis (18, 19) . Previous studies have shown that CPT inhibits angiogenesis in bovine aortic endothelial cells (BAECs) (20) and human umbilical vein endothelial cells (HUVEC) (21) . However, the effect of CPT on lymphangiogenesis is not known.
Vascular endothelial growth factors (VEGFs) and their receptors are central controllers of vasculogenesis, angiogenesis and lymphangiogenesis (22) . Five VEGFs (VEGF or VEGF-A, placenta growth factor, VEGF-B, VEGF-C and VEGF-D) and three VEGF receptors (VEGFR-1, -2 and -3) have been identified in mammals (22) .
VEGFR-1/2 and VFGFR-3 are primarily expressed on the surface of vascular and lymphatic endothelial cells (LECs), respectively (22) . It is known that VEGF-A binds to VEGFR-1/2, regulating vasculogenesis and angiogenesis, while VEGF-C/D binds to VEGFR-3, mediating lymphangiogenesis. In particular, VEGF-C/D binds to and activates VEGFR-3, leading to activation of the downstream signaling molecules, such as phosphatidylinositol 3′-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways, which are crucial for LEC survival and lymphangiogenesis (22, 23) , as well as metastasis (11) (12) (13) . Thus, VEGFR-3 pathway has become an attractive target for cancer prevention and treatment.
The small GTPases (Rac1, Cdc42 and RhoA) regulate migration, survival, and vacuole and capillary lumen formation in LECs, which are critical for lymphangiogenesis (24) (25) (26) (27) . Recent studies have demonstrated a requirement for Rac1 and Cdc42 in capillary lumen formation of LECs, indicating that the small GTPases play key roles in the lymphangiogenic process (28) . Therefore, targeting small GTPases is an alternative approach for cancer prevention and treatment. Using murine LEC tube formation, an in vitro lymphangiogenesis model (29) , we studied the effect of CPT on lymphangiogenesis. The results indicate that CPT inhibited the LEC tube formation, which was in part by inhibition of VEGFR-3-mediated phosphorylation of extracellular signal-related kinase 1/2 (ERK1/2), and in part by inhibition of expression and activities of Rac1 and Cdc42.
Materials and Methods
Chemicals. CPT was extracted from the roots of Salvia miltiorrhiza Bunge (Danshen), as described previously (10) , and dissolved in 100% ethanol to prepare stock solutions (20 mM), which was aliquoted and stored at -20°C. U0126, a selective inhibitor of MKK1/2, was obtained from LC Laboratories (Woburn, MA, USA). Plasmids and transfection. LEC clones stably overexpressing p3×Flag-VEGFR-3-TV1 and p3×Flag-TV1 plasmid (empty vector, as a control) were generated and used as described (29 and Cdc42 were made as described previously (32) , and lentiviral shRNAs against VEGFR-3 and green fluorescence protein (GFP, as a control) were shown (29) .
Subsequently, LEC cells, when grown to about 70% confluence, were infected with the above lentiviral shRNAs in the presence of 8 μg/ml polybrene and exposed to 2 mg/ml puromycin after 24 h of infection. In 5 days, cells were used for experiments. and Rac1 (Ad-Rac1-L61) were described previously (29, 33) . All adenoviruses were amplified, titrated and used as described (33) .
Western blot analysis. Western blot analysis was performed as described previously (32) . The primary antibodies used included antibodies to VEGFR-3, Akt, Cdc42, RhoA, ERK2, JNK1, phospho-JNK (Thr183/Tyr185), p38, Tube formation assay. Tube formation assay was performed, as described previously (29) .
Small GTPase activity assay. The activity of Rac1, Cdc42, or RhoA was determined using Rac/Cdc42 assay kit and Rho assay kit (Millipore, Billerica, MA, USA), respectively, as described previously (33) .
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Statistical analysis.
Results were expressed as mean values ± standard deviation (mean ± SD). The data were analyzed by one-way analysis of variance (ANOVA) followed by post-hoc Dunnett's t-test for multiple comparisons. A level of P < 0.05 was considered to be statistically significant.
Results
CPT inhibits LEC tube formation. Studies have shown that CPT inhibits
angiogenesis (20, 21) , but the effect of CPT on lymphangiogenesis is not known. To CPT inhibition of LEC tube formation is associated with suppressing VEGFR-3 protein expression. Since VEGFR-3 is primarily expressed in LECs (34) , and essential for lymphangiogenesis (11) (12) (13) 22) , we studied whether CPT inhibits LEC tube formation by targeting VEGFR-3. When LECs were treated with CPT (0-10 μM)
for 24 h, a concentration-dependent reduction of VEGFR-3 protein expression was detected by Western blotting (Fig.2A) . When the cells were exposed to CPT at 10 μM, a time-dependent inhibition of VEGFR-3 expression was also observed (Fig.2B) .
Treatment with CPT for 8 h was able to remarkably downregulate VEGFR-3 protein level. Prolonged treatment with CPT resulted in more reduction of VEGFR-3
To define the role of VEGFR-3 in CPT inhibition of LEC tube formation, LEC cells (LEC/VEGFR-3) stably overexpressing VEGFR-3 were generated by transfection with p3×Flag-VEGFR-3-TV1 plasmid, as described (29) . About 3-fold increase of VEGFR-3 protein expression was detected in LEC/VEGFR-3 cells, comparing with the control cells (LEC/V) transfected with the empty vector (Fig.2C , left panel). Overexpression of VEGFR-3 did not alter the cell viability and growth rate in LECs. Treatment with CPT (10 μM) for 24 h inhibited VEGFR-3 protein expression by ~80% (Fig. 2C, left panel) , and suppressed the tube formation by ~90% in LEC/V cells (Fig.2C, right panel) . When LEC/VEGFR-3 cells were exposed to CPT (10 μM) for 24 h, VEGFR-3 protein expression was reduced by ~50%, but the VEGFR-3 protein level was still slightly higher than the basal level in the control (LEC/V) cells (Fig.2C, left panel) . Interestingly, overexpression of VEGFR-3 rendered high resistance to CPT inhibition of the tube formation (Fig.2C, right panel (Fig.3A and B) , and JNK and p38 MAPK pathways obviously (data not shown), but resulted in a concentration-and time-dependent inhibition of phosphorylation of ERK1/2, despite no effect on total protein level of ERK2 (Fig.3A and B), suggesting a selective inhibition of the ERK pathway in the LECs. (Fig.3C) . In contrast, silencing VEGFR-3 by lentiviral shRNA mimicked the effect of CPT, decreasing ERK1/2 phosphorylation (Fig.3D) .
The results reveal that CPT inhibition of ERK1/2 phosphorylation is a consequence of downregulation of VEGFR-3 protein expression in the LECs.
To further verify whether CPT inhibition of LEC tube formation is truly attributed to inhibition of ERK1/2 pathway, we generated recombinant adenoviral vector (Fig.4A) . Of notice, expression of constitutively active MKK1, but not GFP, conferred high resistance to CPT inhibition of LEC tube formation (Fig.4B) . As a control, U0126 (a selective inhibitor of MKK1/2, upstream of ERK1/2) was employed to treat the LECs. We observed that 5 μM U0126 inhibited ERK1/2 phosphorylation almost completely and suppressed the tube formation by 90% in LECs. Addition of 10 μM CPT failed to enhance U0126 inhibition of the tube formation (data not shown). However, treatment with either 2.5 μM U0126 or 5 μM CPT alone inhibited ERK1/2 phosphorylation by ~50% (Fig.4C) , and inhibited LEC tube formation by approximately 60% and 40%, respectively (Fig.4D) . Combined treatment with 2.5 μM U0126 and 5 μM CPT displayed an additive or synergistic inhibitory effect on ERK1/2 phosphorylation and the tube formation ( Fig.4C and D) .
The results suggest that CPT inhibits LEC tube formation partly through targeting VEGFR-3-mediated ERK pathway.
Rac1 and Cdc42, but not RhoA, are involved in CPT inhibition of LEC tube formation. As the small GTPases play critical roles in lymphangiogenesis (24-28), we were also curious to ask whether CPT inhibits LEC tube formation by targeting the small GTPases. When LECs were treated with CPT (0-10 μM) for 24 h or 10ҏ μM CPT for 0-24 h, a concentration-and time-dependent inhibition of protein expression of Rac1 and Cdc42, but not RhoA, was observed ( Fig.5A and B) . Similarly, CPT treatment also markedly decreased the active (GTP-bound) protein levels of Rac1 and Cdc42, but not RhoA (Fig.5C and D) , indicating inhibition of the activities of Rac1
and Cdc42.
To demonstrate the roles of the small GTPases in the CPT inhibition of LEC tube formation, we constructed recombinant adenoviruses encoding constitutively active Rac1 and Cdc42. LECs infected with these adenoviruses were treated with or without CPT, followed by tube formation assay. As shown in Fig.6A , considerable levels of constitutively active Rac1 (Rac1-L61) and Cdc42 (Cdc42-L28) were expressing in LECs, respectively, as detected by Western blotting using antibodies to Flag and individual small GTPases. Expression of Rac1-L61 or Cdc42-L28 alone neither significantly altered the basal tube formation, nor rendered apparent resistance to CPT inhibition of LEC tube formation (Fig.6B) . However, interestingly, concurrent expression of Rac1-L61 and Cdc42-L28 conferred high resistance to CPT inhibition of LEC tube formation (Fig.6B) .
To further corroborate the roles of the small GTPases in CPT inhibition of LEC tube formation, we generated lentiviral shRNAs to silence Rac1 (Fig.6C, left panel) and Cdc42 (Fig.6C, right panel) , respectively. Of interest, downregulation of Rac1 or Cdc42 by ~90% alone was able to inhibit LEC tube formation by ~70% and ~80%, respectively (Fig.6D) . The data suggest that both Rac1 and Cdc42 are essential for LEC tube formation, and CPT inhibits LEC tube formation partly by suppressing expression/activities of the two small GTPases.
Discussion
Recent studies have shown that CPT exhibits anticancer activity by inhibiting proliferation and inducing apoptosis in cancer cells, as well as inhibiting angiogenesis (6) (7) (8) (9) (10) (20) (21) . Here, for the first time, we present evidence that CPT inhibited LEC tube formation, an in vitro lymphangiogenesis model, suggesting that CPT inhibits lymphangiogenesis. It is well accepted that lymphangiogenesis, like angiogenesis, is pivotal for tumor growth and metastasis, and anti-lymphangiogenesis has become a new avenue for prevention and treatment of cancer (11) (12) (13) . Therefore, our findings strongly support the notion that CPT is a potential anticancer agent.
VEGFR-3 has been characterized as a key player for lymphangiogenesis, and disruption of this pathway has been explored for the development of anticancer drugs (36) (37) (38) (39) (40) (41) . In the present study, we found that the anti-lymphangiogenic effect of CPT is 
CPT inhibited LEC tube formation, at least partly through inhibition of VEGFR-3-mediated ERK1/2 pathway.
In our study, we also noticed that overexpression of VEGFR-3 (Fig.2C) or constitutively active MKK1 (Fig.4B) probably by inhibiting VEGFR-3. However, to our surprise, neither overexpression nor downregulation of VEGFR-3 had any influence on activities/expression of Rac1 and Cdc42, regardless of presence or absence of CPT (data not shown), suggesting that Rac1 and Cdc42 are not regulated by VEGFR-3 pathway in our murine LECs. This is probably due to the different cell lines or experimental conditions employed.
Further studies are needed to address whether CPT inhibits lymphangiogenesis in vivo and uncover the underlying molecular mechanisms. Also, more studies should be helpful to unveil how CPT inhibits expression of VEGFR-3, Rac1 and Cdc42.
In summary, we have shown that CPT inhibited LEC tube formation in a concentration-and time-dependent manner. CPT inhibition of the LEC tube formation was related to suppression of VEGFR-3-mediated ERK pathway (Fig.1S) .
Furthermore, our data indicate that CPT inhibition of LEC tube formation was also in part by targeting Rac1and Cdc42 (Fig.1S) . CPT may act as a novel anti-lymphangiogenic agent.
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